Tailored chemo doses may help seniors fight pancreatic cancer while staying independent

NCT ID NCT02143219

Completed Disease control Sponsor: Institut Cancerologie de l'Ouest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a chemotherapy cocktail called FOLFIRINOX in 72 patients aged 70 or older with metastatic pancreatic cancer. The doses were adjusted based on each person's genetics to reduce side effects while still fighting the tumor. The goal was to see if this approach could control the cancer and help patients maintain their ability to perform daily activities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm metastatic malignant neoplasm pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC METASTATIC CANCER TOXICITY

Contacts and locations

Locations

CH Vendée

La Roche-sur-Yon, 85925, France
Centre Eugène marquis

Rennes, 35042, France
Centre Oscar Lambret

Lille, 59020, France
ICM (Val d'Aurelle)

Montpellier, 34298, France
ICO Paul Papin

Angers, 49000, France
ICO René Gauducheau

Saint-Herblain, 44805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.